Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Context: The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes. Objective: We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study. Setting: The study was of an unselected, community-based population comprising 69,016 participants. Main Outcome Measures: FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris. Results: The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0–17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8–13.8). Conclusion: The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The frequency of HeFH in the population has earlier been estimated at 1/500; however, recent studies from whole populations suggest that the frequency is higher, in some populations as high as 1/137. 297”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [297]
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationJones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Self-citationKotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Research works printed but not linked: 1
- World Health Organization, 1999, Familial hypercholesterolaemia (FH)
Cited by
Items 101–200 of 632
Genetic diagnosis of familial hypercholesterolaemia by targeted next‐generation sequencing
Maglio, C., Mancina, R. M., Motta, B. M., Stef, M. A., Pirazzi, C., Palacios, L., Askaryar, N., Borén, J., Wiklund, O., & Romeo, S. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12263 · Cited by 69
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Hovingh, G. K., Raal, F. J., Dent, R. E., Stefanutti, C., Descamps, O. S., Masana, L., Lira, A., Bridges, I. M., Coll, B., & SULLIVAN, D. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.003 · Cited by 65
Epidemiology of familial hypercholesterolaemia: Community and clinical
Vallejo‐Vaz, A. J., & Ray, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.855 · Cited by 72
Béliard, S., Carreau, V., Carrié, A., Giral, P., Duchêne, E., Farnier, M., Ferrières, J., Fredenrich, A., Krempf, M., Luc, G., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.021 · Cited by 59
Paquette, M., Brisson, D., Dufour, R., Khoury, É., Gaudet, D., & Baass, A. W. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.008 · Cited by 62
Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
Mytilinaiou, M. G., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00707 · Cited by 77
Zhang, Y., Liu, J., Li, S., Xu, R.-X., Sun, J., Tang, Y., & Li, J.-J. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-192 · Cited by 55
Vickery, A. W., Bell, D. A., Garton‐Smith, J., Kirke, A. B., Pang, J., & Watts, G. F. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.07.062 · Cited by 59
Self-citationDiagnóstico y tratamiento de la hipercolesterolemia familiar en España: documento de consenso
Mata, P., Rodrigo Alonso, K., Ruiz, A., González‐Juanatey, J. R., Badimón, L., Díaz-Díaz, J. L., Múñoz, M. T., Muñiz-Grijalvo, O., Galve, E., Irigoyen, L., et al. (2014) · Atención Primaria · doi:10.1016/j.aprim.2013.12.015 · Cited by 60
Miname, M. H., & Santos, R. D. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.003 · Cited by 61
Management of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 68
Lipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martín, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 65
The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data
Ramaswami, U., Cooper, J. A., & Humphries, S. E. (2016) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308570 · Cited by 56
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Villa, G., Löthgren, M., Kutikova, L., Lindgren, P., Gandra, S. R., Fonarow, G. C., Sorio, F., Masana, L., Bayés‐Genís, A., & van Hout, B. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.02.011 · Cited by 58
Migliara, G., Baccolini, V., Rosso, A., D’Andrea, E., Massimi, A., Villari, P., & Vito, C. D. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00252 · Cited by 55
Gallo, A., Charriere, S., Vimont, A., Chapman, M. J., Angoulvant, D., Boccara, F., Cariou, B., Carreau, V., Carrié, A., Bruckert, E., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.06.011 · Cited by 52
Familial Hypercholesterolemia Prevalence Among Ethnicities—Systematic Review and Meta-Analysis
Toft-Nielsen, F., Emanuelsson, F., & Benn, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.840797 · Cited by 66
Self-citationLahtinen, A. M., Havulinna, A. S., Jula, A., Salomaa, V. V., & KONTULA, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.11.015 · Cited by 60
Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning
Pina, A. F., Helgadóttir, S., Mancina, R. M., Pavanello, C., Pirazzi, C., Montalcini, T., Henriques, R., Calabresi, L., Wiklund, O., Macedo, M. P., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319898951 · Cited by 57
Barriers, facilitators, and solutions to familial hypercholesterolemia treatment
Jones, L. K., Sturm, A. C., Seaton, T., Gregor, C. M., Gidding, S. S., Williams, M. S., & Rahm, A. K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244193 · Cited by 56
Genetic diagnosis of familial hypercholesterolemia in Han Chinese
Chiou, K.-R., & Charng, M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.009 · Cited by 53
de Isla, L. P., Watts, G. F., Alonso, R., Díaz-Díaz, J. L., Muñiz-Grijalvo, O., Zambón, D., Fuentes, F. J., de Andrés, R., Padró, T., López‐Miranda, J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1066 · Cited by 56
Self-citationPang, J., SULLIVAN, D. R., Harada‐Shiba, M., Ding, P. Y. A., Selvey, S., Ali, S., & Watts, G. F. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.011 · Cited by 50
Self-citationBrett, T., Qureshi, N., Gidding, S. S., & Watts, G. F. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.019 · Cited by 56
Self-citationNorsworthy, P. J., Vandrovcová, J., Thomas, E. R. A., Campbell, A., Kerr, S. M., Biggs, J., Gamé, L., Soutar, A. K., Smith, B. H., Dominiczak, A. F., et al. (2014) · BMC Medical Genetics · doi:10.1186/1471-2350-15-70 · Cited by 54
Pang, J., Hu, M., Lin, J., Miida, T., Nawawi, H. M., Park, J. E., Wu, X., Ramli, A. S., Kim, N., Kwok, S., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017817 · Cited by 52
Self-citationPająk, A., Szafraniec, K., Polak, M., Drygas, W., Piotrowski, W., Zdrojewski, T. R., & Jankowski, P. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59700 · Cited by 62
Knowns and unknowns in the care of pediatric familial hypercholesterolemia
Martin, A. C., Gidding, S. S., Wiegman, A., & Watts, G. F. (2017) · Journal of Lipid Research · doi:10.1194/jlr.s074039 · Cited by 49
Self-citationBogsrud, M. P., Langslet, G., Wium, C., Johansen, D., Svilaas, A., & Holven, K. B. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.11.009 · Cited by 49
Mandraffino, G., Scicali, R., Rodríguez-Carrio, J., Savarino, F., Mamone, F., Scuruchi, M., Cinquegrani, M., Imbalzano, E., Di Pino, A., Piro, S., et al. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.01.015 · Cited by 48
Kirke, A. B., Barbour, R., Burrows, S., Bell, D. A., Vickery, A. W., Emery, J. D., & Watts, G. F. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.09.011 · Cited by 52
Self-citationThe genetics of familial hypercholesterolemia and emerging therapies
Vogt, A. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s44315 · Cited by 52
Stefanutti, C., Blom, D. J., Averna, M. R., Meagher, E. A., Theron, H. D., Marais, A. D., Hegele, R. A., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.014 · Cited by 46
Béliard, S., Boccara, F., Cariou, B., Carrié, A., Collet, X., Farnier, M., Ferrières, J., Krempf, M., Peretti, N., Rabès, J., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.010 · Cited by 50
Dyrbuś, K., Gąsior, M., Desperak, P., Osadnik, T., Nowak, J. U., & Banach, M. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.899 · Cited by 60
Wald, D. S., Bangash, F., & Bestwick, J. P. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.01.014 · Cited by 47
Kline, G. A., Chin, A., So, B., Harvey, A. M., & Pasieka, J. L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12669 · Cited by 46
Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes
Alonso, R., Mata, P., Zambón, D., Mata, N., & Fuentes, F. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.7 · Cited by 44
World Heart Federation Cholesterol Roadmap
Murphy, A., Faria-Neto, J. R., Al-Rasadi, K., Blom, D., Catapano, A., Cuevas, A., Lopez-Jimenez, F., Perel, P., Santos, R., Sniderman, A., et al. (2017) · Global Heart · doi:10.1016/j.gheart.2017.03.002 · Cited by 43
Self-citationMy Approach to the Patient With Familial Hypercholesterolemia
Safarova, M. S., & Kullo, I. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.013 · Cited by 46
Ohmura, H., Fukushima, Y., Mizuno, A., Niwa, K., Kobayashi, Y., Ebina, T., Kimura, K., Ishibashi, S., & Daida, H. (2017) · International Heart Journal · doi:10.1536/ihj.16-188 · Cited by 44
Al‐Rasadi, K., Al-Zakwani, I. S., Alsheikh-Ali, A. A. A., Almahmeed, W. A., Rashed, W. A., Ridha, M., Santos, R. D., & Zubaid, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.003 · Cited by 43
Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry
AlHabib, K. F., Al‐Rasadi, K., Almigbal, T. H., Batais, M. A., Al-Zakwani, I. S., Al-Allaf, F. A., Al-Waili, K., Zadjali, F., AlGhamdi, M. A., Alnouri, F., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251560 · Cited by 51
Watts, G. F., Ding, P. Y. A., George, P. M., Hagger, M. S., Hu, M., Lin, J., Lin, K. K., Marais, A. D., Miida, T., Nawawi, H. M., et al. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.35949 · Cited by 43
Self-citationRerup, S. A., Bang, L. E., Mogensen, U. M., Engstrøm, T., Jørgensen, E. O., Pedersen, F., Torp-Pedersen, C. T., Gislason, G., James, S. K., Hagström, E., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.08.001 · Cited by 45
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Kramer, A. I., Trinder, M., & Brunham, L. R. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.06.017 · Cited by 53
Cohen, H., Stefanutti, C., Giacomo, S. D., Morozzi, C., Widhalm, K., Bjelakovic, B. B., Berni, A., Martino, F., & Bosco, G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00926-3 · Cited by 49
Li, Q., Campan, A., Ren, A., & Eid, W. E. (2022) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2022.104786 · Cited by 40
Vishwanath, R. L., & Hemphill, L. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.11.002 · Cited by 41
Meshkov, A. N., Ershova, A. I., Kiseleva, A. V., Shalnova, S. A., Drapkina, O. M., Boytsov, S. A., & on behalf of the FH-ESSE-RF Investigators (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060464 · Cited by 47
Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis
Iatan, I., Akioyamen, L. E., Ruel, I. L., Guérin, A., Hales, L., Coutinho, T. A., Brunham, L. R., & Genest, J. J. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae417 · Cited by 46
Bos, S., Duvekot, M. H. C., Blommesteijn-Touw, A. C., Verhoeven, A. J. M., Mulder, M. T., Watts, G. F., Sijbrands, E. J. G., & van Lennep, J. E. R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.024 · Cited by 39
Self-citationOoi, E. M. M., Barrett, P. H. R., & Watts, G. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.069 · Cited by 42
Self-citationFamilial Hypercholesterolemia in Asian Populations
Zhou, M., & Zhao, D. H. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34405 · Cited by 41
Li, S., Zhang, Y., Zhu, C., Guo, Y., Wu, N., Gao, Y., Qing, P., Li, X., Sun, J., Liu, G., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.013 · Cited by 41
Ershova, A. I., Meshkov, A. N., Бажан, С. С., Сторожок, М. А., Efanov, А. Y., Medvedeva, I. V., Владимировна, И. Е., Danilchenko, Y. V., Kuzmina, O. K., Барбараш, О. Л., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181148 · Cited by 41
Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia
Sarraju, A., & Knowles, J. W. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00005 · Cited by 46
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features
Bertolini, S., Calandra, S., Arca, M., Averna, M. R., Catapano, A. L., Tarugi, P., Bartuli, A., Bucci, M., Buonuomo, P. S., Calabrò, P., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.027 · Cited by 42
Bos, S., Phillips, M. R., Watts, G. F., Verhoeven, A. J. M., Sijbrands, E. J. G., & Ward, N. C. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.03.014 · Cited by 38
Self-citationMedication therapy disease management: Geisinger’s approach to population health management
Jones, L. K., Greskovic, G. A., Grassi, D. M., Graham, J., Sun, H., Gionfriddo, M. R., Murray, M. F., Manickam, K., Nathanson, D. C., Wright, E. A., et al. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp161061 · Cited by 40
Banach, M., Mazidi, M., Mikhailidis, D. P., Toth, P. P., Jozwiak, J. J., Rysz, J., & Watts, G. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy527 · Cited by 42
Self-citationSanin, V., Schmieder, R. S., Ates, S., Schlieben, L. D., Wiehler, J., Sun, R., Decker, M., Sander, M., Holdenrieder, S., Kohlmayer, F., et al. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac007 · Cited by 45
Molecular basis of familial hypercholesterolemia
Bruikman, C. S., Hovingh, G. K., & Kastelein, J. J. P. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000385 · Cited by 35
Leipold, R. J., Raal, F. J., Ishak, J., Hovingh, K., & Phillips, H. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317730473 · Cited by 38
A consensus statement on lipid management after acute coronary syndrome
Schiele, F., Farnier, M., Krempf, M., Bruckert, É., Ferrières, J., Angoulvant, D., Boccara, F., Bonnet, J., Bonnet, J., Bruckert, E., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616679791 · Cited by 42
Kullo, I. J., Olson, J. E., Fan, X., Jose, M. T., Safarova, M. S., Breitkopf, C. R., Winkler, E. M., Kochan, D. C., Snipes, S., Pacyna, J. E., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.06.026 · Cited by 36
Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia
Perry, C. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0030-7 · Cited by 35
Scicali, R., Pino, A. D., Platania, R., Purrazzo, G., Ferrara, V., Giannone, A., Urbano, F., Filippello, A., Rapisarda, V., Farruggia, E., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.07.003 · Cited by 36
Harada, P. H. N., Miname, M. H., Benseñor, I. M., Santos, R. D., & Lotufo, P. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.021 · Cited by 35
Talmud, P. J., Futema, M., & Humphries, S. E. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000090 · Cited by 41
Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges
Schmidt, E. B., Hedegaard, B. S., & Retterstøl, K. (2020) · Heart · doi:10.1136/heartjnl-2019-316276 · Cited by 35
Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia
Koh, N., Ference, B. A., Nicholls, S. J., Návar, A. M., Chew, D. P., Kostner, K., He, B., Tse, H., Dalal, J. J., Santoso, A., et al. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.36 · Cited by 36
The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results
Al‐Rasadi, K., AlHabib, K. F., Al-Allaf, F. A., Al-Waili, K., Al-Zakwani, I. S., Al-Sarraf, A. J., Almahmeed, W. A., Al-Sayed, N., AlGhamdi, M. A., Batais, M. A., et al. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666181005125459 · Cited by 35
Green, P., Neely, D., Humphries, S. E., Saunders, T., Gray, V., Gordon, L., Payne, J., Carter, S., Neuwirth, C. K. Y., Rees, A., et al. (2015) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12481 · Cited by 32
Knowing the Prevalence of Familial Hypercholesterolemia Matters
Goldberg, A. C., & Gidding, S. S. (2016) · Circulation · doi:10.1161/circulationaha.116.021673 · Cited by 36
Pang, J., Lansberg, P. J., & Watts, G. F. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34108 · Cited by 33
Self-citationWalsh, M. T., & Hussain, M. M. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1221883 · Cited by 36
The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
Kumar, R., Tonkin, A. M., Liew, D., & Zomer, E. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.04.122 · Cited by 33
Sirtori, C. R., Pavanello, C., & Bertolini, S. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.931100 · Cited by 31
Prediction of cardiovascular risk in patients with familial hypercholesterolaemia
Villa, G., Wong, B. J. O., Kutikova, L., Ray, K. K., Mata, P., & Bruckert, É. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx011 · Cited by 36
The functional landscape of coding variation in the familial hypercholesterolemia gene LDLR
Tabet, D. R., Coté, A. G., Lancaster, M. C., Weile, J., Rayhan, A., Fotiadou, I., Kishore, N., Li, R., Kuang, D., Knapp, J. J., et al. (2025) · Science · doi:10.1126/science.ady7186 · Cited by 44
Stefanutti, C., Morozzi, C., Giacomo, S. D., Sovrano, B., Mesce, D., & Grossi, A. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.009 · Cited by 32
Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?
Paynter, N. P., Ridker, P. M., & Chasman, D. I. (2016) · Circulation Research · doi:10.1161/circresaha.115.306360 · Cited by 36
Brunham, L. R., Cermakova, L., Lee, T., Priecelova, I., Alloul, K., de Chantal, M., Francis, G. A., & Frohlich, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.08.016 · Cited by 35
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 37
Familial hypercholesterolaemia: PCSK9 inhibitors are coming
Santos, R. D., & Watts, G. F. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61702-5 · Cited by 34
Self-citationBell, D. A., Hooper, A. J., Edwards, G., Southwell, L., Pang, J., BOCKXMEER, F. M. V., Watts, G. F., & Burnett, J. R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.04.002 · Cited by 30
Self-citationWhat is new in familial hypercholesterolemia?
Santos, R. D., & Maranhão, R. C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000073 · Cited by 31
Bellgard, M., Walker, C. E., Napier, K. R., Lamont, L., Hunter, A. A., Render, L., Radochonski, M., Pang, J., Pedrotti, A., SULLIVAN, D. R., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.37507 · Cited by 31
Self-citationScicali, R., Pino, A. D., Pavanello, C., Ossoli, A., Strazzella, A., Albertí, A., Mauro, S. D., Scamporrino, A., Urbano, F., Filippello, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56857-2 · Cited by 30
Mariano, C., Alves, A. C., Medeiros, A. M., Chora, J. R., Antunes, M. C. D. S., Futema, M., Humphries, S. E., & Bourbon, M. (2019) · Clinical Genetics · doi:10.1111/cge.13697 · Cited by 31
Familial hypercholesterolaemia: A pressing issue for European health care
Brice, P., Burton, H., Edwards, C. W., Humphries, S. E., & Aitman, T. J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.019 · Cited by 29
New Approaches in Detection and Treatment of Familial Hypercholesterolemia
Hartgers, M. L., Ray, K. K., & Hovingh, G. K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0665-x · Cited by 37
Yamashita, S., Masuda, D., Harada‐Shiba, M., Arai, H., Bujo, H., Ishibashi, S., Daida, H., Koga, N., & Oikawa, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62764 · Cited by 31
Can Patients be Accurately Assessed for Familial Hypercholesterolaemia in Primary Care?
Bell, D. A., Kirke, A. B., Barbour, R., Southwell, L., Pang, J., Burrows, S., & Watts, G. F. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.06.015 · Cited by 29
Self-citationMortensen, M. B., Kulenovic, I., Klausen, I. C., & Falk, E. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.002 · Cited by 29
Iyen, B., Qureshi, N., Kai, J., Akyea, R. K., Leonardi‐Bee, J., Roderick, P. J., Humphries, S. E., & Weng, S. F. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.017 · Cited by 30
Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats
Etxebarria, A., Benito‐Vicente, A., Stef, M. A., Ostolaza, H., Palacios, L., & Martín, C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.026 · Cited by 31
Metadata
- Authors
- Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- The University of Western Australia (AU)
- The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark
- Corresponding author
- Nordestgaard, Børge G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-11-01
- Volume
- 97
- Issue
- 11
- Pages
- 3956-3964
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1993634977
- Cited by
- 632
- References
- 38
- Citations by year
- 2026: 28 · 2025: 23 · 2024: 28 · 2023: 37 · 2022: 42 · 2021: 36 · 2020: 44 · 2019: 48 · 2018: 61 · 2017: 80 · 2016: 92 · 2015: 53 · 2014: 42 · 2013: 15 · 2012: 1
- FWCI
- 36.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Sundhed og Sygdom, Det Frie Forskningsråd
- Regeneron Pharmaceuticals
- Gentofte Hospital
- Herlev Hospital
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- familial hypercholesterolemia, prevalence, coronary artery disease, cholesterol-lowering drugs, LDLR mutations, APOB mutations, Dutch Lipid Clinic Network criteria, underdiagnosis, undertreatment, myocardial infarction, angina pectoris, Copenhagen General Population Study
- MeSH terms
- Aged, Anticholesteremic Agents, Coronary Artery Disease, Denmark, Female, Genotype, Humans, Hyperlipoproteinemia Type II, Lipids, Lipoproteins, Male, Middle Aged, Risk, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.